Daily Cosmetic Research Analysis
Three studies reshape cosmetic and reconstructive practice today: a preclinical mechanistic study shows PCL biostimulatory filler strengthens adipose septa via collagen and elastin regeneration; a meta-analysis finds no proven cosmetic benefit of mesh “internal bra” in breast surgery despite similar complication rates; and a retrospective cohort shows extended antibiotics offer no added protection after second-stage breast reconstruction.
Summary
Three studies reshape cosmetic and reconstructive practice today: a preclinical mechanistic study shows PCL biostimulatory filler strengthens adipose septa via collagen and elastin regeneration; a meta-analysis finds no proven cosmetic benefit of mesh “internal bra” in breast surgery despite similar complication rates; and a retrospective cohort shows extended antibiotics offer no added protection after second-stage breast reconstruction.
Research Themes
- Biostimulatory fillers and adipose tissue remodeling
- Evidence appraisal of support meshes in aesthetic breast surgery
- Antibiotic stewardship in implant-based breast reconstruction
Selected Articles
1. Enhancement of Fat Septa: Polycaprolactone (PCL) Microspheres Boost Collagen Production in Subcutaneous Adipose Tissue.
In a rat model, PCL-based biostimulatory filler increased type I/III collagen within adipose septa and promoted elastin regeneration over 4 months, with similar effects in juvenile and aged animals. Multimodal analyses (histology, immunostaining, qPCR, EVG, SEM) support an age-independent, robust remodeling response.
Impact: This study elucidates the tissue-level mechanism of a widely used biostimulatory filler, linking PCL microspheres to septal collagen/elastin remodeling in adipose tissue. It provides a mechanistic basis to guide product selection and treatment planning in aesthetic and reconstructive practice.
Clinical Implications: Supports considering PCL fillers when the goal is septal reinforcement and tissue quality improvement rather than purely volumization; however, human histologic correlation and patient-reported outcomes are needed before changing standards.
Key Findings
- PCL-based filler significantly increased type I and III collagen within adipose interstitium (septal regions) on histology and immunostaining.
- Elastica van Gieson staining showed enhanced elastin regeneration, mitigating age-related decline.
- qPCR confirmed upregulation of collagen-related gene expression consistent with biostimulation.
Methodological Strengths
- Multimodal assessment (Masson trichrome, immunostaining, SEM, qPCR, EVG) increases mechanistic confidence.
- Age-stratified comparison (juvenile vs aged rats) demonstrates age-independent effects.
Limitations
- Preclinical rat model limits generalizability to humans.
- Sample size and detailed dose–response and safety characterization were not specified; no clinical outcomes.
Future Directions: Human histologic validation and correlation with clinical outcomes (elasticity, volumetric persistence, adverse events); dose, plane, and combination therapy optimization; long-term remodeling trajectories.
BACKGROUND: The reduction in collagen content within the subcutaneous fat layer due to aging results in thinning and weakening of the fibrous septum, leading to an unstable fat pad. Studies on the mechanism of action of polycaprolactone (PCL) collagen stimulators in the adipose layer are lacking. OBJECTIVES: This research aimed to explore the effectiveness of PCL-based filler in enhancing the fibrous septum within adipose tissue, thereby facilitating collagen and elastin synthesis in the adipose layer, while also comparing the disparities in the process between juvenile and aged individuals. METHODS: A rat model was utilized to study subcutaneous fat implantation effects of PCL-based filler. Over 4 months, the impact on fibrous septum formation was evaluated with Masson's trichrome staining and immunostainings for Types I and III collagen, and a structural evaluation through scanning electron microscopy analysis. PCL-induced collagenization mechanisms were explored by quantitative polymerase chain reaction (qPCR). Elastin regeneration was examined with Elastica van Gieson (EVG) staining. RESULTS: Histological analysis demonstrated that PCL-based filler effectively stimulated collagen fiber formation in subcutaneous adipose tissue in both juvenile and aged rats. Immunostainings indicated significant promotion of Types I and III collagen regeneration, primarily within the interstitial spaces among adipocytes, as well as its confirmation at the genetic level through qPCR analysis. EVG staining further unveiled the role of PCL in promoting elastin production while mitigating age-related decline. CONCLUSIONS: PCL-based filler enhanced fat septum regeneration and deposition, demonstrating a robust, age-independent response. These findings suggest PCL-based fillers as promising therapeutic agents for rejuvenating subcutaneous adipose tissue and enhancing skin volume and elasticity in cosmetic and reconstructive contexts.
2. Efficacy of Mesh Use in Breast Surgery: A Comprehensive Review of Complications and Aesthetic Outcomes.
This meta-analysis indicates that mesh-assisted “internal bra” techniques do not show superior cosmetic outcomes and have similar complication rates compared with non-mesh approaches. The authors call for well-controlled, quantitative studies with standardized aesthetic metrics.
Impact: Challenges widespread claims about mesh improving aesthetics, encouraging critical appraisal and potentially avoiding unnecessary costs and risks in cosmetic breast surgery.
Clinical Implications: Mesh should not be assumed to enhance aesthetics; case selection should be individualized, and shared decision-making should weigh complication risk, cost, and the lack of proven cosmetic benefit.
Key Findings
- Pooled infection/abscess rate with mesh was approximately 3.6%, with no clear risk advantage versus non-mesh approaches.
- Current literature lacks quantitative evidence that mesh improves aesthetic outcomes.
- Standardized, controlled comparative studies are needed to objectively assess cosmetic benefits.
Methodological Strengths
- Meta-analytic synthesis of complication rates across studies.
- Inclusion of patient-reported and aesthetic outcomes in the review.
Limitations
- High heterogeneity and limited randomized evidence reduce certainty.
- Aesthetic outcome measures and follow-up durations were not standardized across studies.
Future Directions: Prospective comparative trials and registries using standardized aesthetic scales and patient-reported outcomes to quantify mesh benefit or lack thereof.
BACKGROUND: The insertion of a mesh "internal bra" has been used in cosmetic breast procedures for soft-tissue reinforcement as a means to mitigate postoperative ptosis. However, there have been concerns regarding complications as a result of mesh placement and a lack of quantitative data regarding postoperative cosmetic outcomes. METHODS: Articles that assessed the effects of the mesh internal bra for soft-tissue support on cosmetic and patient-reported outcomes, complications, and surveillance were reviewed. Meta-analysis was performed to determine the overall complication rates, and cosmetic outcomes and patient-reported outcomes were reviewed. RESULTS: Meta-analysis showed the following summary effect sizes: infection/abscess had a pooled rate of 3.61% ( CONCLUSIONS: Although there does not seem to be a significant difference in risk profile with and without the use of mesh, the current data do not support the claims of improved cosmetic outcomes. Well-controlled, quantitative studies are necessary to objectively evaluate the cosmetic benefits of using mesh.
3. The effect of prophylactic antibiotics on second-stage breast reconstruction: A retrospective analysis.
In 359 second-stage implant-based reconstructions, extending prophylactic antibiotics beyond a single perioperative cefazolin dose did not reduce 3-month infection rates (p=0.581). Prior breast infection history was the only significant predictor of postoperative infection (p<0.001).
Impact: Provides practice-informing, real-world evidence to curtail unnecessary antibiotic use in second-stage breast reconstruction, aligning with antimicrobial stewardship.
Clinical Implications: Restrict prophylaxis to a single perioperative cefazolin dose for most patients; prioritize risk stratification for those with prior breast infection and minimize adverse events and resistance by avoiding prolonged courses.
Key Findings
- Extended prophylactic antibiotics (1–6 days or ≥7 days) did not reduce 3-month postoperative infection after second-stage implant exchange (p=0.581).
- History of breast infection was an independent predictor of postoperative infection (p<0.001).
- Limiting antibiotics to a single perioperative dose may reduce adverse events and antimicrobial resistance without increasing infections.
Methodological Strengths
- Single-center consistency with multivariate logistic regression in a sizable cohort (n=359).
- Dose–duration stratification enabled assessment of potential duration–effect relationships.
Limitations
- Retrospective, single-center design with potential residual confounding; not randomized.
- Potential variability in antibiotic selection and perioperative management details.
Future Directions: Prospective, risk-stratified trials comparing minimal effective prophylaxis regimens; evaluation of patient-centered outcomes and microbiome/AMR impacts.
BACKGROUND: Implant-based breast reconstruction has a higher infection risk than cosmetic augmentation, leading to routine prophylactic antibiotic use. We previously found extended prophylaxis reduced infections during the first-stage reconstruction with tissue expander/acellular dermal matrix placement. However, the most appropriate antibiotic class and duration of prophylaxis in the second-stage reconstruction remains unclear. This retrospective study aims to address this gap, focusing on antibiotic selection and duration during second-stage implant-based breast reconstruction. METHODS: A single-center retrospective cohort study involved 359 patients undergoing second-stage breast reconstruction with tissue expander-implant exchange between January 2018 and January 2021. Chart reviews were performed to collect patient and surgical factors, antibiotic prophylaxis information, and postoperative outcomes. Multivariate logistic regression and likelihood ratio tests assessed associations between prophylaxis, covariates, and complications. RESULTS: Beyond a single perioperative dose of cefazolin, extended antibiotic prophylaxis did not significantly affect postoperative infection likelihood after second-stage breast reconstruction. Patients were grouped by antibiotic prophylaxis duration: 0 days (62 patients), 1 to 6 days (58 patients), and 7 or more days (239 patients). Extending antibiotic prophylaxis duration did not improve the prediction of 3-month postoperative infection rate (p = 0.581). A previous history of breast infection was a significant predictor for infection (p < 0.001). CONCLUSION: Extending antibiotics prophylaxis beyond a single preoperative dose of intravenous cefazolin does not reduce complication rates for patients undergoing second-stage breast reconstruction. Limiting prolonged prophylactic antibiotic use beyond the anesthetic period may reduce side effects (e.g., upset GI tract) and associated complications, including allergic reactions, Clostridium difficile colitis, and the emergence of new antibiotic-resistant pathogens.